Cargando…

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is routinely used for advanced or metastasized neuroendocrine tumours (NET). To prevent nephrotoxicity, positively charged amino acids (AA) are co-infused. The aim of this study was to correlate the risk for therapy-related hyperkalaemia with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lapa, Constantin, Werner, Rudolf A, Bluemel, Christina, Lückerath, Katharina, Schirbel, Andreas, Strate, Alexander, Buck, Andreas K, Herrmann, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412194/ https://www.ncbi.nlm.nih.gov/pubmed/25977877 http://dx.doi.org/10.1186/s13550-014-0046-2

Ejemplares similares

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy
por: Werner, Rudolf A., et al.
Publicado: (2016)

Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
por: Lapa, Constantin, et al.
Publicado: (2018)

DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy
por: Eberlein, Uta, et al.
Publicado: (2015)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values
por: Lapa, Constantin, et al.
Publicado: (2017)

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
por: Lapa, Constantin, et al.
Publicado: (2016)

(18)FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
por: Lapa, Constantin, et al.
Publicado: (2014)

Radionuclide Imaging of Neurohormonal System of the Heart
por: Chen, Xinyu, et al.
Publicado: (2015)

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
por: Lapa, Constantin, et al.
Publicado: (2017)

(11)C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma
por: Lückerath, Katharina, et al.
Publicado: (2015)

Targeting Paraprotein Biosynthesis for Non-Invasive Characterization of Myeloma Biology
por: Lückerath, Katharina, et al.
Publicado: (2013)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

(11)C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement
por: Lapa, Constantin, et al.
Publicado: (2016)

Tumor-Associated Macrophages in Glioblastoma Multiforme—A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy?
por: Lapa, Constantin, et al.
Publicado: (2015)

Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography
por: Kosmala, Aleksander, et al.
Publicado: (2022)

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging
por: Buder, Kristina, et al.
Publicado: (2014)

Detection Rate of (68)Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy
por: Brumberg, Joachim, et al.
Publicado: (2020)

Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
por: Werner, Rudolf A., et al.
Publicado: (2017)

CXCR4-Directed Imaging in Solid Tumors
por: Werner, Rudolf A., et al.
Publicado: (2019)

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
por: Werner, Rudolf A., et al.
Publicado: (2016)

The next era of renal radionuclide imaging: novel PET radiotracers
por: Werner, Rudolf A., et al.
Publicado: (2019)

Novel CYP11B-ligand [(123/131)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience
por: Heinze, Britta, et al.
Publicado: (2021)

Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
por: Bluemel, Christina, et al.
Publicado: (2016)

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
por: Lapa, Constantin, et al.
Publicado: (2016)

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
por: Philipp-Abbrederis, Kathrin, et al.
Publicado: (2015)

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Early biochemical and radiographic response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
por: Cytawa, Wojciech, et al.
Publicado: (2023)

(11)C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions
por: Lapa, Constantin, et al.
Publicado: (2017)

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Precautions in the management of patients who have received therapeutic amounts of radionuclides
por: National Council on Radiation Protection and Measurements. Washington, DC
Publicado: (1970)

(68)Gallium- and (90)Yttrium-/(177)Lutetium: “theranostic twins” for diagnosis and treatment of NETs
por: Werner, Rudolf A., et al.
Publicado: (2014)

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
por: Jahn, Ulrika, et al.
Publicado: (2023)

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers
por: Weich, Alexander, et al.
Publicado: (2022)

Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
por: Fodi, Christina-Katharina, et al.
Publicado: (2022)

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
por: Werner, R.A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0rh9k9e38flpn8k3ii2i683rjq